BioXcel Therapeutics Inc (NASDAQ:BTAI) price on current trading day, rose 7.73% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.37.
A look at the stock’s price movement, the close in the last trading session was $2.20, moving within a range at $2.25 and $3.1005. The beta value (5-Year monthly) was 0.898. Turning to its 52-week performance, $49.58 and $1.72 were the 52-week high and 52-week low respectively. Overall, BTAI moved 4.41% over the past month.
BioXcel Therapeutics Inc’s market cap currently stands at around $7.80 million, with investors looking forward to this quarter’s earnings report slated for on 2024-Nov-13.
Analysts have a consensus estimate of 718.26k for the company’s revenue for the quarter, with a low and high estimate of 150k and 2.34M respectively. The average forecast suggests up to a 91.03% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 2.84M, representing a 106.09% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BTAI is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 7 recommend BTAI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BTAI’s current price about -1.81% and -38.69% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 43.98, while 7-day volatility ratio is 19.31% and 29.52% in the 30-day chart. Further, BioXcel Therapeutics Inc (BTAI) has a beta value of 0.60, and an average true range (ATR) of 0.69. Analysts have given the company’s stock an average 52-week price target of $1, forecast between a low of $1 and high of $1. Looking at the price targets, the low is 57.81% off current price level while to achieve the yearly target high, price needs to move 57.81%. Nonetheless, investors will most likely welcome a 57.81% jump to $1 which is the analysts’ median price.
If we refocus on BioXcel Therapeutics Inc (NASDAQ:BTAI), historical trading data shows that trading volumes averaged 1.17 over the past 10 days and 4.70 million over the past 3 months. The company’s latest data on shares outstanding shows there are 3.29 million shares.
The 16.85% of BioXcel Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 16.42% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.33 million on 2025-02-28, giving us a short ratio of 0.07. The data shows that as of 2025-02-28 short interest in BioXcel Therapeutics Inc (BTAI) stood at 1229.0 of shares outstanding, with shares short rising to 0.25 million registered in 2025-01-31. Current price change has pushed the stock -60.38% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BTAI stock continues to rise going into the next quarter.
